

06-18-2002

Form PTO-1595
(Rev. 03/01)
OMB No. 0651-0027 (exp. 5/31/2)
Tab settings ⇌ ⇌ ⇌ ▼



102126252

HEET

U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

1. Name of conveying party(ies):
Novartis Finance Corporation
6.7.02
Additional name(s) of conveying party(ies) attached? Yes No

2. Name and address of receiving party(ies)
Name: Syngenta Investment Corporation
Internal Address: _____
Street Address: 2 Righter Parkway
City: Wilmington State: DE Zip: 19803
Additional name(s) & address(es) attached? Yes No

OFFICE OF PATTENT RECORDS
FINANCE SECTION
JUN -7 AM 9:47

3. Nature of conveyance:
 Assignment Merger
 Security Agreement Change of Name
 Other _____
Execution Date: May 30, 2002

4. Application number(s) or patent number(s):
If this document is being filed together with a new application, the execution date of the application is: _____
A. Patent Application No.(s) 09/988,462
Additional numbers attached? Yes No

B. Patent No.(s) See attached
Assignment

5. Name and address of party to whom correspondence concerning document should be mailed:
Name: Larry W. Stults, Ph.D.
Internal Address: Patent Department
Street Address: 3054 Cornwallis Road
City: RTP State: NC Zip: 27709

6. Total number of applications and patents involved: 8
7. Total fee (37 CFR 3.41).....\$ 320.00
 Enclosed (See PTO Form 2038)
 Authorized to be charged to deposit account any additional fees

8. Deposit account number:
50-1744

DO NOT USE THIS SPACE

9. Signature.
Gregory W. Warren
Name of Person Signing

Gregory W. Warren
Signature

June 4, 2002
Date

Reg. No. 48,385 Total number of pages including cover sheet, attachments, and documents: 4

Mail documents to be recorded with required cover sheet information to:
Commissioner of Patents & Trademarks, Box Assignments
Washington, D.C. 20231

06/17/2002 LNUELLER 00000100 09900462

01 FC:501

320.00 OP

PATENT
REEL: 012983 FRAME: 0152

ASSIGNMENT

Whereas, Novartis Finance Corporation, 608 Fifth Avenue, New York, NY 10020, a corporation of New York, is the assignee and legal owner of the entire right, title and interest in each of the following United States patents and patent applications;

USSN	US Patent Number
07/951,715	5,625,136
08/459,504	6,075,185
08/460,408	6,051,760
08/459,595	6,018,104
08/459,448	5,859,336
08/459,444	6,121,014
09/547,422	6,320,100
09/988,462	- - - - -

Whereas, the Novartis Finance Corporation board of directors adopted a resolution ("Resolution") on October 31, 2000 for the purposes of contributing to the capital of Syngenta Investment Corporation, 2 Righter Parkway, Wilmington, DE 19803, a corporation of Delaware, any patents, trademarks or other intellectual property held by Novartis Finance Corporation and exclusively used in the Novartis agribusiness companies; and

Whereas, Novartis Finance Corporation wishes to assign its entire interest in each of the United States patents and patent applications listed above to Syngenta Investment Corporation and said Syngenta Investment Corporation wishes to acquire Novartis Finance Corporation's interest in said patents and patent applications.

Now, therefore, Novartis Finance Corporation hereby assigns to Syngenta Investment Corporation and its successors and assigns its entire right, title and interest in (a) each of the United States patents and patent applications listed above, (b) any and all continuations and divisions of said applications (including further continuations and divisions such as, but not limited to, continuations and divisions of continuations), (c) any and all patents that may be issued and/or granted on all of said applications, (d) any and all applications for reissues of said patents, (e) any and all reissues of said patents that may be issued and/or granted, (f) any and all applications for extensions of said patents (including reissue patents) and for reexamination certificates for said patents (including reissue patents) and (g) any and all extensions of said patents (including reissue patents) that may be issued and/or granted and reexamination certificates that may be issued for said patents (including reissue patents), said right, title and interest conveyed herein by Novartis Finance Corporation constituting the entire right, title and interest in said applications, patents (including reissue patents), extensions and reexamination certificates.

In witness whereof, Novartis Finance Corporation has caused this Assignment to be signed by its duly authorized corporate officer.

Signed this 30th day of May 2002.

Novartis Finance Corporation

Wayne P. Merkelson
~~Thomas Hoxie~~ Wayne P. Merkelson
Vice-President & General Counsel